Market Research Logo

Myotonic Dystrophy - Pipeline Review, H2 2016

Myotonic Dystrophy - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Myotonic Dystrophy - Pipeline Review, H2 2016’, provides an overview of the Myotonic Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myotonic Dystrophy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myotonic Dystrophy
  • The report reviews pipeline therapeutics for Myotonic Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myotonic Dystrophy therapeutics and enlists all their major and minor projects
  • The report assesses Myotonic Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myotonic Dystrophy
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myotonic Dystrophy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myotonic Dystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Myotonic Dystrophy Overview
Therapeutics Development
Pipeline Products for Myotonic Dystrophy - Overview
Pipeline Products for Myotonic Dystrophy - Comparative Analysis
Myotonic Dystrophy - Therapeutics under Development by Companies
Myotonic Dystrophy - Therapeutics under Investigation by Universities/Institutes
Myotonic Dystrophy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Myotonic Dystrophy - Products under Development by Companies
Myotonic Dystrophy - Products under Investigation by Universities/Institutes
Myotonic Dystrophy - Companies Involved in Therapeutics Development
AMO Pharma Limited
BioMarin Pharmaceutical Inc.
F. Hoffmann-La Roche Ltd.
Ionis Pharmaceuticals, Inc.
Marina Biotech, Inc.
Sarepta Therapeutics, Inc.
WAVE Life Sciences Ltd.
Myotonic Dystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISDMPK-2.5Rx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IUCT-169 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IUCT-290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IUCT-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LR-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mexiletine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRO-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target RNA for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Myotonic Dystrophy Type 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tideglusib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-0411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myotonic Dystrophy - Dormant Projects
Myotonic Dystrophy - Discontinued Products
Myotonic Dystrophy - Product Development Milestones
Featured News & Press Releases
Sep 19, 2013: AmorChem invests in the development of a therapeutic to treat myotonic dystrophy
Dec 20, 2012: Scripps Florida Scientists Create New Approach to Destroy Disease-Associated RNAs in Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Myotonic Dystrophy, H2 2016
Number of Products under Development for Myotonic Dystrophy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Myotonic Dystrophy - Pipeline by AMO Pharma Limited, H2 2016
Myotonic Dystrophy - Pipeline by BioMarin Pharmaceutical Inc., H2 2016
Myotonic Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Myotonic Dystrophy - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Myotonic Dystrophy - Pipeline by Marina Biotech, Inc., H2 2016
Myotonic Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016
Myotonic Dystrophy - Pipeline by WAVE Life Sciences Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Myotonic Dystrophy - Dormant Projects, H2 2016
Myotonic Dystrophy - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Myotonic Dystrophy, H2 2016
Number of Products under Development for Myotonic Dystrophy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report